Product imageResearch use only

CAT. NO. DC49932Featured

FTT5

Research highlights

Branched-ester biodegradable tailsLong-mRNA deliveryMouse liver base editingOriginal four-component recipe retained

Pack size & price

USD

Add the cited formulation componentsSelected FTT5 pack + every supporting component at 100 mg each+US$450 / set

Supporting components

DOPE DC33634 · 100 mg+Cholesterol DCD-041 · 100 mg+DMG-PEG2000 DC40169 · 100 mg

Components are supplied separately; this is not a premixed LNP. RNA/cargo, buffer and formulation service are not included.

Total$980

We match the best price and quality on market.

Ships from ShanghaiIce-pack transportPure lipid recommended

Product overview

Description & Application

FTT5 is a lipid-like compound for efficient delivery of long mRNAs in vivo.

CAS No.	2328129-27-5
Chemical Name	FTT5
Synonyms	FTT-5， FTT 5
SMILES	C(C1C=C(C(=O)NCCCN(CCCCCCCCC(=O)OC(CCC)CCCC)CCCCCCCCC(=O)OC(CCC)CCCC)C=C(C(=O)NCCCN(CCCCCCCCC(=O)OC(CCC)CCCC)CCCCCCCCC(=O)OC(CCC)CCCC)C=1)(=O)NCCCN(CCCCCCCCC(=O)OC(CCC)CCCC)CCCCCCCCC(=O)OC(CCC)CCCC
Formula	C120H222N6O15
M.Wt	1989.08
Purity	>95% by ELSD-HPLC
Storage	Pure form: −20 °C, 1 year; In solvent: −80 °C, 6 months; −20 °C, 1 month. Sealed and protected from light.
Shipping condition	Ships from Shanghai. Pure lipid is stable during ice-pack transport.
Publication	Zhang X, Zhao W, Nguyen GN, et al. Functionalized lipid-like nanoparticles for in vivo mRNA delivery and base editing. Science Advances. 2020;6(34):eabc2315.

Literature guide · DC49932

Formulation & Performance

Study-specific compositions, preparation conditions and experimental outcomes for FTT5.

Formulations Preparation Particle data Performance Interpretation References

Evidence coverage

Full article and complete SI reviewed; liver reporter, FVIII replacement, base editing and lipid clearance are separated.

1. Formulations and component amounts

Reported composition and calculated mass are separate. Molecular-weight inputs use the current catalog values; DMG-PEG2000 is fixed initially at 2507. Edit inputs only when using a verified alternative material.

Original in vivo FTT5 recipe

molar parts (sum 90.75)Main formulation Methods

Total lipid mass (mg)

Component	Normalized mol%	Amount (µmol)	Weight (mg)
FTT5	22.039	25.1735	50.0720
DOPE	33.058	37.7602	28.0947
Cholesterol	44.077	50.3469	19.4666
DMG-PEG2000	0.826	0.9440	2.3666

Calculated total: 100.0000 mg lipid. RNA, solvent and process loss are excluded.

The mass worksheet uses the existing catalog molecular-weight input (1989.07791852951).

How component weights are calculated

For total lipid mass M (mg), molar parts rᵢ and molecular weight MWᵢ: component mass = M × rᵢ × MWᵢ / Σ(r × MW). Component amount (µmol) = component mass (mg) × 1000 / MWᵢ. Molar parts are normalized only for the displayed percentage. The calculation does not infer N/P or RNA dose.

2. Preparation and experimental setup

Parameter	Reported procedure / limitation	Source
Assembly	Lipids dissolved in ethanol; RNA in citrate buffer. Pipette mixing for in vitro tests; microfluidic formulation for in vivo experiments and cryo-TEM.	Materials and Methods
Unspecified process values	The reviewed protocol does not establish an exact citrate pH, flow ratio, total flow or N/P for this recipe.	Not filled from another lipid protocol
Optimization outcome	Some optimized recipes performed better in vitro but worse in vivo. The original composition was retained for subsequent in vivo work.	SI Figs. S4–S5
Cargo mapping	FVIII mRNA and adenine-base-editor mRNA/sgRNA were studied in separate dose and endpoint experiments.	Main Figs. 3–4

3. Particle characterization

Measurement / batch	Reported result	Evidence context
Original FTT5 LNP	Approximately 100 nm; PDI <0.2; zeta potential approximately −11 mV; encapsulation approximately 91%	Main Fig. 2
Molar-ratio basis	The reported entries sum to 90.75 parts	Normalized only for the mass calculation
Neat-lipid shelf life	Not established by formulated-particle or clearance experiments	Follow the supplied batch documentation

4. Performance by experiment

Find an experiment

Experiment and dose	Readout and comparator	Result and source
Hepatic reporter expression C57BL/6 mice; intravenous Fluc mRNA 0.5 mg/kg	Readout: 6 h Comparator: TT3 formulation	Approximately twofold greater liver expression; the reported organ signal is normalized by tissue weight.Main Fig. 2; n=2
Lipid clearance Intravenous RNA dose 1.8 mg/kg; lipid amounts measured in liver	Readout: 20 min, 6 h, 24 h and 48 h Comparator: FTT9 and other study formulations	FTT5 retained approximately half of its liver lipid amount at 48 h. The >80% removal at 6 h and complete removal by 24 h belong to FTT9, not FTT5.Main Fig. 2; n=3
FVIII protein supplementation Wild-type and hemophilia-A mice; FVIII mRNA 2 mg/kg IV	Readout: 6 h and 12 h Comparator: Study control groups	FVIII concentrations exceeded 140 ng/mL in wild-type mice and 220 ng/mL in hemophilia-A mice at the reported points. These are protein-expression endpoints.Main Fig. 3; n=3
FVIII functional activity Hemophilia-A mice; same 2 mg/kg FVIII-mRNA study	Readout: 6 h and 12 h Comparator: 1 IU/mL defined as 100% activity standard	Reported activity approximately 73% and 90%, respectively; not a percentage of corrected liver cells.Main Fig. 3; n=3
Adenine base editing BALB/c mice; ABE mRNA:sgRNA 1:1 by mass; intravenous total-RNA dose response	Readout: Day 7 targeted sequencing Comparator: TT3 comparison and dose-response controls	Editing plateaued near 60% at 1 mg/kg. The reported ED50 <0.125 mg/kg describes the dose-response fit, not necessarily 50% absolute editing.Main Fig. 4; n=5; SI Fig. S7
Short-term histology Hemophilia-A mice; FVIII mRNA 2 mg/kg IV	Readout: 72 h Comparator: Study controls	No evident abnormalities were reported in examined sections. Repeat-dose, long-term and human tolerability are not established by this endpoint.Main Fig. 3 / SI safety assessment

Mechanistic evidence

Inhibitor experiments in Hep3B cells reported reduced uptake with several pathway inhibitors; calcein-release observations support endosomal escape. These assays do not establish an exclusive entry mechanism.

5. Interpretation and unresolved details

Do not assign FTT9 rapid-clearance values to FTT5.
Improved cell-culture activity after reformulation did not translate into improved in vivo expression.
Adenine editing, FVIII protein concentration and coagulation activity use different denominators and cannot be combined as one efficacy percentage.

Results apply to the stated LNP composition, cargo, process, dose, route and model. LNP experimental measurements are not batch-release specifications for the isolated lipid.

6. References and data access

Zhang X, Zhao W, Nguyen GN, et al. Functionalized lipid-like nanoparticles for in vivo mRNA delivery and base editing. Science Advances. 2020;6(34):eabc2315.

DOI: 10.1126/sciadv.abc2315

Download experiment table (CSV) · Open printable Formulation & Performance guide

Revision FP-20261022 · Source review: 22 October 2026 · DC Chemicals

Laboratory planning

Solution Calculators

The product molecular weight is prefilled when available and remains editable. Confirm solvent compatibility and solubility before preparation.

The paper reports a 20:30:40:0.75 molar ratio, not mol%. The calculator normalizes the four values to 100% only for weight calculation. It uses the catalog FTT5 average MW 1989.07791852951 and project-standard component MWs; confirm the exact PEG-lipid MW before use.

Mass = concentration × volume × molecular weight

MassConcentrationVolumeMolecular weightg/mol

Enter any three values to calculate the fourth.

C₁V₁ = C₂V₂

C₁mMV₁mLC₂mMV₂mL

Enter any three values to calculate the fourth.

Preparing stock solutions

Quick preparation table

Solvent volumes update from the molecular weight above.

Mass	1 mM	5 mM	10 mM
10 mg	5.0275 mL	1.0055 mL	502.75 μL
25 mg	12.5686 mL	2.5137 mL	1.2569 mL
50 mg	25.1373 mL	5.0275 mL	2.5137 mL
100 mg	50.2746 mL	10.0549 mL	5.0275 mL
250 mg	125.6864 mL	25.1373 mL	12.5686 mL

Need a different pack size or technical document?

Contact our team with the catalog number and requested quantity.

Handling guidance

Shipping, storage and sampling

How is the lipid shipped, and how should I store it?

We generally ship the neat (undissolved) lipid compound rather than an ethanol solution. The neat lipid is stable during transport with ice packs, and shipments originate from Shanghai. Pure form: store at −20 °C for up to 1 year. In solvent: store at −80 °C for up to 6 months or at −20 °C for up to 1 month. Keep sealed and protected from light. Avoid repeated thaw cycles for best results.

Pure lipid or solution — which should I choose?

Pure lipid is generally more stable during shipping and storage, so we usually recommend the pure form. A solution in ethanol or chloroform can be supplied when required by your workflow. Tell us the intended application, solvent and target concentration so the most suitable format can be confirmed.

How should I measure a small amount of oily or viscous lipid?

Ionizable lipids are often oily liquids or viscous semisolids, so material can be lost during repeated weighing or transfer. For a small pack, dissolve the entire quantity and aliquot it volumetrically. For example, add 1 mL ethanol to 25 mg lipid to prepare a 25 mg/mL stock, then use a pipette to withdraw the required amount. For quantities above 100 mg, direct weighing with an analytical balance may be more practical. Always confirm solvent compatibility and solubility first.

Can you support formulation optimization and scale-up?

Yes. Share the RNA cargo, target tissue, administration route, formulation method and assay plan. Our team can discuss starting molar ratios, N/P ratio and scale-up requirements for research workflows.

FTT5

Pack size & price

Description & Application

Recommended Products

LP-01

CKK-E12

5A2-SC8

246C10

SM-102

C12-200

TCL053

Iso-A11B5C1

Lipid A4B4-S3

lipid 11-10-8